The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhai, Y.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhai, Y.
Right arrow Articles by Rosenberg, S. A.

The Journal of Immunology, Vol 156, Issue 2 700-710, Copyright © 1996 by American Association of Immunologists

ARTICLES

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy

Y Zhai, JC Yang, Y Kawakami, P Spiess, SC Wadsworth, LM Cardoza, LA Couture, AE Smith and SA Rosenberg
Surgery Branch, National Cancer Institute, National Institute of Health Bethsda, MD 20892, USA.

The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. In order to develop immunizing vectors for the treatment of patients with metastatic melanoma, replication-defective recombinant adenoviruses, Ad2CMV-MART1 and Ad2CMV-gp100, which encode these tumor Ags, have been generated. Infection of non-Ag expressing HLA-A2+ cell lines A375 and MDA-231 with the vectors resulted in recognition by Ag-specific CTLs as demonstrated by specific target cell lysis and release of cytokines, including IFN-gamma, TNF-alpha, and granulocyte-macrophage-CSF. Sodium butyrate and TNF-alpha can further augment adenovirus-mediated transgene expression and increase recognition by specific CTLs. Although adenovirus-infected cells expressed the E3/19K protein at detectable levels, significant reduction of surface MHC class I expression was observed in only 3 of 10 tumor cell lines infected with either Ad2CMV-MART1 or Ad2CMV-gp100. Because of the suspected homology between the human MART1 and gp100 genes and their murine counterparts, we immunized C57BL/6 mice with these recombinant adenoviruses and demonstrated that immunization with Ad2CMV-gp100 could protect mice from murine melanoma B16 challenge administered intradermally. Depletion of CD8+ but not CD4+ T cells in vivo from Ad2CMV-gp100- vaccinated mice eliminated the protective effect. The anti-gp100 T cells induced by Ad2CMV-gp100 vaccinated appeared to be responsible for the protection. Thus, these recombinant adenoviruses encoding tumor Ags may be useful as vaccines to induce specific T cell immunity for cancer therapy.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. V. Vaidya, S. E. Stepp, M. E. McNerney, J.-K. Lee, M. Bennett, K.-M. Lee, C. L. Stewart, V. Kumar, and P. A. Mathew
Targeted Disruption of the 2B4 Gene in Mice Reveals an In Vivo Role of 2B4 (CD244) in the Rejection of B16 Melanoma Cells
J. Immunol., January 15, 2005; 174(2): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
L. C. van Dinten, N. Pul, A. F. van Nieuwpoort, C. J. Out, M. J. Jager, and P. J. van den Elsen
Uveal and Cutaneous Melanoma: Shared Expression Characteristics of Melanoma-Associated Antigens
Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 24 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
G. Dadaglio, S. Morel, C. Bauche, Z. Moukrim, F. A. Lemonnier, B. J. Van den Eynde, D. Ladant, and C. Leclerc
Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes
Int. Immunol., December 1, 2003; 15(12): 1423 - 1430.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Korst and R. G. Crystal
Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification
Ann. Thorac. Surg., October 1, 2003; 76(4): 1319 - 1326.
[Abstract] [Full Text] [PDF]

Home page
 Crit. Rev. Oral Biol. Med.Home page
K. Devaraj, M. L. Gillison, and T.-C. Wu
DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Crit. Rev. Oral. Biol. Med., September 1, 2003; 14(5): 345 - 362.
[Abstract] [Full Text] [PDF]

Home page
 fake Crit Rev Oral Biol MedHome page
K. Devaraj, M. L. Gillison, and T.-C. Wu
DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Critical Reviews in Oral Biology & Medicine, September 1, 2003; 14(5): 345 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Du, A. J. Miller, H. R. Widlund, M. A. Horstmann, S. Ramaswamy, and D. E. Fisher
MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma
Am. J. Pathol., July 1, 2003; 163(1): 333 - 343.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies
Blood, March 1, 2003; 101(5): 1905 - 1912.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Bollard, C. Rossig, M. J. Calonge, M. H. Huls, H.-J. Wagner, J. Massague, M. K. Brenner, H. E. Heslop, and C. M. Rooney
Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity
Blood, May 1, 2002; 99(9): 3179 - 3187.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
K. Haupt, M. Roggendorf, and K. Mann
The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy
Experimental Biology and Medicine, April 1, 2002; 227(4): 227 - 237.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Kurnick, T. Ramirez-Montagut, L. A. Boyle, D. M. Andrews, F. Pandolfi, P. J. Durda, D. Butera, I. S. Dunn, E. M. Benson, S. J. P. Gobin, et al.
A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter
J. Immunol., August 1, 2001; 167(3): 1204 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. L. Rakhmilevich, M. Imboden, Z. Hao, M. D. Macklin, T. Roberts, K. M. Wright, M. R. Albertini, N.-S. Yang, and P. M. Sondel
Effective Particle-mediated Vaccination against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor
Clin. Cancer Res., April 1, 2001; 7(4): 952 - 961.
[Abstract] [Full Text]

Home page
 BloodHome page
J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas
Blood, March 1, 2001; 97(5): 1370 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. R. Siemens, B. D. Elzey, D. M. Lubaroff, C. Bohlken, R. J. Jensen, A. K. Swanson, and T. L. Ratliff
Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix
J. Immunol., January 15, 2001; 166(2): 731 - 735.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D.-W. Liu, Y.-P. Tsao, C.-H. Hsieh, J.-T. Hsieh, J. T. Kung, C.-L. Chiang, S.-J. Huang, and S.-L. Chen
Induction of CD8 T Cells by Vaccination with Recombinant Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Reduces Tumor Growth
J. Virol., October 1, 2000; 74(19): 9083 - 9089.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Y. Wan, J. Bramson, A. Pilon, Q. Zhu, and J. Gauldie
Genetically Modified Dendritic Cells Prime Autoreactive T Cells through a Pathway Independent of CD40L and Interleukin 12: Implications for Cancer Vaccines
Cancer Res., June 1, 2000; 60(12): 3247 - 3253.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
D. Valmori, F. Levy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Lienard, V. Cerundolo, J.-C. Cerottini, and P. Romero
Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue
J. Immunol., January 15, 2000; 164(2): 1125 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter
Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo
Cancer Res., October 1, 1999; 59(19): 4955 - 4963.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Kaplan, Q. Yu, S. T. Piraino, S. E. Pennington, S. Shankara, L. A. Woodworth, and B. L. Roberts
Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens
J. Immunol., July 15, 1999; 163(2): 699 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. Butterfield, A. Koh, W. Meng, C. M. Vollmer, A. Ribas, V. Dissette, E. Lee, J. A. Glaspy, W. H. McBride, and J. S. Economou
Generation of Human T-cell Responses to an HLA-A2.1-restricted Peptide Epitope Derived from {{alpha}}-Fetoprotein
Cancer Res., July 1, 1999; 59(13): 3134 - 3142.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
E. A. Hirschowitz and R. G. Crystal
Adenovirus-Mediated Expression of Interleukin-12 Induces Natural Killer Cell Activity and Complements Adenovirus-Directed gp75 Treatment of Melanoma Lung Metastases
Am. J. Respir. Cell Mol. Biol., May 1, 1999; 20(5): 935 - 941.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole
Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination
Clin. Cancer Res., May 1, 1999; 5(5): 1173 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. H. Butterfield, S. M. Jilani, N. G. Chakraborty, L. A. Bui, A. Ribas, V. B. Dissette, R. Lau, S. C. Gamradt, J. A. Glaspy, W. H. McBride, et al.
Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus
J. Immunol., November 15, 1998; 161(10): 5607 - 5613.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Tuting, C. C. Wilson, D. M. Martin, Y. L. Kasamon, J. Rowles, D. I. Ma, C. L. Slingluff Jr., S. N. Wagner, P. van der Bruggen, J. Baar, et al.
Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-{alpha}
J. Immunol., February 1, 1998; 160(3): 1139 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. E. M. Toes, R. C. Hoeben, E. I. H. van der Voort, M. E. Ressing, A. J. van der Eb, C. J. M. Melief, and R. Offringa
Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
PNAS, December 23, 1997; 94(26): 14660 - 14665.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.